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Objectives This study sought to assess whether incorporation of routine bleeding risk estimates affected the utilization of
bivalirudin during percutaneous coronary intervention (PCI).
Background Bivalirudin use during PCI has been shown to reduce bleeding complications. However, a risk–treatment paradox
exists, in which patients at highest risk for bleeding are least likely to receive bivalirudin. Whether routine esti-
mation of individualized bleeding risk can affect physicians’ use of bivalirudin is unknown.
Methods PCI data from a single health system between 2007 and 2011 were analyzed. Beginning in July 2009, individu-
alized bleeding risk estimates were provided immediately preceding PCI. Using a pre–post design, we compared
bivalirudin use before and after this implementation, for patients across 3 strata of bleeding risk (1%, 1% to
3%, and 3%).
Results Data from 6,491 PCI procedures were analyzed. Overall, bivalirudin use increased in the post-implementation
period (26.9% vs. 34.2%, p  0.001). Bivalirudin use increased in intermediate (27% to 35%, p  0.001) and
high bleeding risk patients (25% to 43%, p  0.001), and decreased in low-risk patients (30% to 25%, p 
0.014). During the same period, bleeding complications decreased in intermediate-risk (3.4% to 1.8%, p 
0.009) and high-risk (6.9% to 3.7%, p  0.005) patients and remained unchanged in low-risk patients (1.1% to
1.0%, p  0.976).
Conclusions There was an increase in bivalirudin use and a lower incidence of bleeding after the incorporation of individual-
ized bleeding risk estimates into clinical practice. This implementation led to a reversal of the risk–treatment
paradox, through a rational increase in bivalirudin use in patients at intermediate and high bleeding risk and
decreased use in lower-risk patients. (J Am Coll Cardiol 2013;61:1847–52) © 2013 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.017Percutaneous coronary intervention (PCI) is a well-
established procedure for the treatment of stable and unsta-
ble coronary artery disease, with approximately 600,000 PCI
procedures performed annually in the United States alone
(1). Although the safety of PCI has improved substantially
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2013, accepted February 14, 2013.over time, post-procedural bleeding remains common (0.2%
to 9.1% in various studies) (2–6), with wide center-level
variability (7). Furthermore, PCI-related bleeding is asso-
ciated with increased short- and long-term mortality (2),
increased risk of myocardial infarction (2) and stroke (8),
prolonged hospital stay, and increased healthcare costs (9).
However, patients’ bleeding risk can be estimated using a
number of available risk prediction models (10,11). For
example, the National Cardiovascular Data Registry
(NCDR) bleeding risk model (12) can be used to classify
patients as having low (1%), intermediate (1% to 3%), or
high bleeding risk (3%) based on 9 pre-procedural clinical
variables.
Bivalirudin use is an established bleeding avoidance
strategy and reduces the incidence of major bleeding across
a broad spectrum of patients undergoing PCI for stable and
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(3,4,13–15). Importantly, the
benefit of bivalirudin in terms of
bleeding reduction is greatest in
patients at highest risk for bleed-
ing (16). However, there exists a
“risk–treatment paradox” with
respect to the use of bivalirudin,
whereby patients who are most
likely to benefit from its use (i.e.,
patients at increased risk for
bleeding) are least likely to re-
ceive it (16).
In July 2009, our health system prospectively incorpo-
rated the NCDR bleeding risk model into the informed
consent document for patients undergoing PCI, in an effort
to support the more rational use of bivalirudin in patients
with the greatest potential to benefit. In this implementa-
tion study, we retrospectively compared bivalirudin utiliza-
tion at 4 centers before and after July 2009, and compared
these data to national trends in bivalirudin use during PCI.
Bivalirudin use was the primary outcome for this analysis for
several reasons. First, bivalirudin is a proven bleeding
avoidance strategy, and data supporting other strategies,
such as radial PCI and vascular closure devices (VCDs), are
less robust (17,18). Second, the benefit of bivalirudin is
limited only to bleeding reduction, whereas the benefits of
radial PCI and VCDs include early ambulation, improved
patient comfort, and improved throughput (18,19). There-
fore, the decision to utilize radial PCI and VCDs involves
factors other than the bleeding risk alone. Finally, bivaliru-
din is available for use to nearly all patients undergoing PCI,
whereas the use of radial PCI is limited to those operators
facile with the technique, and the use of VCDs is dependent
on the patient’s access site anatomy.
Methods
Approval for this retrospective analysis was obtained from
the health system’s institutional review board. Data from all
PCIs between 2007 and 2011 performed at 4 PCI centers in
a single healthcare system were included for analysis. In July
2009, the NCDR bleeding risk model was incorporated into
a software platform, ePRISM (Health Outcomes Sciences,
LLC, Overland Park, Kansas) (20,21), to generate individ-
ualized bleeding risk estimates for all patients undergoing
non-emergent coronary angiography and possible PCI.
Each patient’s demographic and clinical information was
entered into the ePRISM application before the procedure,
and the individualized bleeding risk estimates were incor-
porated into the informed consent document. Both the
patients and physicians had ready access to this information.
The NCDR bleeding risk model has been described previ-
ously (12) and incorporates 9 pre-procedural clinical vari-
ables: acute coronary syndrome type, cardiogenic shock, sex,
Abbreviations
and Acronyms
NCDR  National
Cardiovascular Data
Registry
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
VCD  vascular closure
deviceprior heart failure, prior PCI, New York Heart Associationfunctional class IV heart failure, peripheral vascular disease,
age, and estimated glomerular filtration rate. The bleeding
risk was displayed in the catheterization laboratory, and the
laboratory staff was educated to inform the interventional
cardiologist of the bleeding risk before PCI. A quarterly
assessment of post-PCI bleeding complications was also
initiated, and individual operators were provided with their
own operator-level data for personal review.
For this analysis, patients were stratified into 3 subgroups
according to bleeding risk: low (1%), intermediate (1% to
3%), and high (3%), as in prior studies categorizing
bleeding risk (16,22). Demographic and clinical variables
of the population before and after implementation of
prospective risk stratification were compared using the
Student t test for continuous variables and chi-square or
Fisher exact test for categorical variables, as appropriate.
Bivalirudin use during PCI was compared before and after
July 2009 using a chi-square test. The trend in bivalirudin
use across the 3 risk strata before and after incorporation of
routine pre-procedural bleeding risk estimates was also
compared using a test for trend. To quantify the effect of
bleeding risk and bivalirudin use between the 2 time
periods, we developed an adjusted logistic regression model
predicting bivalirudin use and including an interaction term
between bleeding risk and time (before or after July 2009).
To identify independent predictors of bivalirudin use, a
multivariable logistic regression analysis was performed.
To compare the data from our institution with national
trends of bivalirudin use during the same time period, data
from the NCDR Cath PCI Registry were analyzed. All
patients in the registry from 2007 to 2011 with sufficient
data to calculate a bleeding score were included in the
analysis. Patients were stratified into low-, intermediate-,
and high-risk bleeding strata as outlined in the previous
text, and bivalirudin use was compared within strata of
bleeding risk, before and after July 2009.
To quantify whether observed changes in care were
consistent across operators, we included a 3-way interaction
between operator, bleeding risk, and time period for the
operators present at our institution in both the pre- and
post-implementation periods (9 of 12 total operators). A
nonsignificant interaction would signify that a change in the
pattern of bivalirudin use is consistent across operators. A
median odds ratio was also calculated to evaluate the effect
of the operator on the use of bivalirudin (23).
To evaluate the impact of pre-procedural bleeding risk
estimation on bleeding, we also assessed the incidence of
major bleeding complications before and after July 2009.
Major bleeding complications were identified using the
CathPCI Registry version 3.0 and 4.0 data collection form
definitions. In version 3.0, bleeding was defined as sus-
pected bleeding from any location requiring transfusion,
prolonged hospital stay, or a drop in hemoglobin 3.0 g/dl.
In version 4.0, a bleeding event was defined as suspected
bleeding with transfusion, a drop in hemoglobin of 3.0
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May 7, 2013:1847–52 Bleeding Risk and Bivalirudin Useg/dl, or a procedural intervention to correct the bleeding
event.
All statistical analyses were performed using the statistical
analysis software (SAS, version 9.2, SAS Institute, Cary,
North Carolina). A two-sided p value0.05 was used as the
criterion for statistical significance.
Results
A total of 6,491 PCI procedures were performed between
2007 and 2011. The baseline demographic and clinical
characteristics of patients undergoing PCI before and after
the routine incorporation of bleeding risk estimates into
clinical practice are presented in Table 1. The mean age of
patients undergoing PCI was 64.8  12.4 years, 68% of
patients were male, 15% presented with STEMI, and 54%
with non-STEMI/unstable angina.
Relationship between bivalirudin use and bleeding risk.
Bleeding risk estimates were introduced into clinical prac-
tice in July 2009. As shown in Figure 1A, the use of
bivalirudin increased in the post-implementation period
(26.9% before July 2009 to 34.2% after July 2009, p 
0.001). Bivalirudin use increased in patients at intermediate
(27% to 35%, p 0.001) and high (25% to 43%, p 0.001)
risk for bleeding, and there was a decrease in bivalirudin
utilization in patients at low bleeding risk (30% to 25% p 
0.014). The change in the trend of bivalirudin use across
strata of bleeding risk was statistically significant (Fig. 1B).
Relationship between bleeding and bleeding risk. Post-
CI bleeding complications decreased after the introduction
f prospective risk stratification (Fig. 2). Bleeding rates in
atients at low bleeding risk were similar before and after
Baseline Clinical and Demographic VariablesTable 1 Baseline Clinical and Demographic
Pre-Implementa
(n  3,652)
Age, yrs 64.3 12.4
Female 1,190 (32.6%
BMI, kg/m2 30.0 6.3
Lack of insurance 205 (5.6%)
GFR 69.8 25.6
Smoking 1,029 (28.2%
Hypertension 2,941 (80.5%
Cerebrovascular disease 558 (15.3%
Peripheral vascular disease 501 (13.7%
Previous PCI 1,575 (43.1%
Previous CABG 686 (18.8%
Previous CHF 392 (10.7%
STEMI 543 (14.9%
NSTEMI/UA 1,984 (54.3%
Bleeding risk
Low 855 (23.4%
Intermediate 1,820 (49.8%
High 977 (26.8%
Values are mean  SD or n (%).
BMI  body mass index; CABG  coronary artery bypass graft; Cnon–ST-segment elevation myocardial infarction; PCI  percutaneous corona
UA  unstable angina.July 2009 (1.1% vs. 1.0%, p  0.976); however, they
ecreased significantly in intermediate-risk (3.4% to 1.8%,
 0.009) and high-risk patients (6.9% to 3.7%, p 
.005).
atient characteristics associated with bivalirudin use. In
he post-implementation time period, only bleeding risk
nd prior CABG were independent predictors of bivalirudin
se, whereas in the pre-implementation time period, smok-
ng status, lack of insurance, hypertension, prior cerebrovas-
ular disease, and history of renal failure were also indepen-
ent predictors (Table 2). Between 2007 and July 2009, for
very 1% increase in bleeding risk, bivalirudin use decreased
y 6%, whereas after July 2009, bivalirudin use increased 7%
ith every 1% increase in bleeding risk. In patients at high
leeding risk, age, history of renal failure, and STEMI were
dentified as independent predictors of use, and STEMI was
he strongest predictor for the lack of bivalirudin use in
atients at high risk for bleeding (odds ratio: 0.43, 95%
onfidence interval: 0.30 to 0.64).
hysician variability. After implementing prospective risk
tratification, the pattern of greater bivalirudin use in
atients at lower bleeding risk was generally reversed across
ll interventionalists, and a 3-way interaction between time,
perator, and the bleeding risk was not statistically signifi-
ant (p  0.31). However, there was substantial variability
n bivalirudin use across operators at our institution, even
fter incorporation of bleeding risk estimates, with the
edian odds ratio for bivalirudin  2.77, suggesting that if
patients with identical clinical characteristics presented to
random interventional cardiologists at our institution,
here was, on average, an approximately 3-fold greater
bles
Post-Implementation
(n  2,839) p Value
65.5 12.2 0.001
899 (31.7%) 0.432
29.8 6.3 0.286
150 (5.3%) 0.562
78.3 29.2 0.001
723 (25.5%) 0.015
2,397 (84.4%) 0.001
507 (17.9%) 0.005
469 (16.5%) 0.002
1,278 (45.0%) 0.128
568 (20.0%) 0.216
430 (15.1%) 0.001
440 (15.5%) 0.483
1,507 (53.1%) 0.319
771 (27.2%) 0.002
1,369 (48.2%)
699 (24.6%)
ongestive heart failure; GFR  glomerular filtration rate; NSTEMI Varia
tion
)
)
)
)
)
)
)
)
)
)
)
)
)
HF  c
ry intervention; STEMI  ST-segment elevation myocardial infarction;
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compared with another.
Comparison of bivalirudin use with contemporary controls.
There were 1,329,881 PCI procedures reported in the
Cath-PCI Registry between 2007 and July 2009, and
Figure 1 Bivalirudin Use
(A) Overall bivalirudin use in the pre- and post-implementation periods.
(B) Bivalirudin use in patients at low (1%), intermediate (1% to 3%), and high
(3%) bleeding risk.
Figure 2
Bleeding Rates in Patients at Low (<1%),
Intermediate (1% to 3%),
and High (>3%) Bleeding Risk
Bleeding rates before incorporation of bleeding risk estimates into clinical prac-
tice are depicted in blue, and bleeding rates after implementation are depicted
in red.1,471,082 procedures between July 2009 and 2011. The
rates of bivalirudin use in the Cath PCI Registry between
2007 and July 2009 were 49%, 45%, and 39% in the low,
intermediate, and high bleeding risk strata, respectively
(Fig. 3). Bivalirudin use was higher in all 3 strata of bleeding
risk in the time period after July 2009, and there was no
observed change in the trend to use bivalirudin more often
in patients at low risk for bleeding (60%, 56%, and 52% in
the low, intermediate, and high bleeding risk strata, respec-
tively), in contrast with the changes in bivalirudin use
observed at our institution.
Discussion
The present study demonstrates that the use of prospective
bleeding risk estimates at the point of care was associated
with increased bivalirudin use in patients at intermediate or
high bleeding risk, and decreased use in patients at low risk.
This pattern was consistently observed across all operators,
although substantial variation in the absolute frequency of
bivalirudin use was present at the operator level. Moreover,
a comparison with other institutions in the Cath-PCI
Figure 3 Bivalirudin Use in Contemporary Cohort
of Patients From the CathPCI Registry
Patients at low (1%), intermediate (1% to 3%), and high (3%) bleeding risk
are depicted in blue, red, and green, respectively.
Independent Predictors of Bivalirudin UseTable 2 Independent Predictors of Bivalirudin Use
Pre-Implementation (2007–2009) Post-Implementation (2009–2011)
Variable
Odds Ratio
(95% CI) Variable
Odds Ratio
(95% CI)
Bleeding risk* 0.94 (0.90–0.97) Bleeding risk* 1.07 (1.04–1.10)
Hypertension 1.38 (1.12–1.68) Prior coronary
bypass
1.30 (1.07–1.56)
Cerebrovascular
disease
1.32 (1.11–1.67)
Tobacco use 0.77 (0.65–0.92)
Lack of
insurance
0.55 (0.37–0.82)
Renal failure 0.45 (0.30–0.96)
*Odds ratio for bleeding risk corresponds to the change in probability in bivalirudin use for every 1%
increase in bleeding risk.
CI  confidence interval.
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associated with a similar trend in the change of bivalirudin
use nationally. These findings are of great importance
because more judicious use of bleeding avoidance strategies
such as bivalirudin in the patients most likely to benefit may
have a tremendous impact on patient outcomes following
PCI.
Bleeding is a common complication of PCI and is
associated with increased morbidity and mortality (2,7,8).
Because the risk of bleeding is both predictable, and
modifiable, bleeding is an ideal target for quality improve-
ment in PCI. Bivalirudin is an accepted alternative to
heparin in patients undergoing PCI (24), and has proven
efficacy in reducing periprocedural bleeding, with no
increased risk of ischemic events (3,4,13–15,25–27). Impor-
tantly, the reduction in bleeding with bivalirudin is depen-
dent on patients’ underlying bleeding risk. In a propensity-
matched study of patients stratified by bleeding risk, the
greatest reduction in bleeding with bivalirudin was observed
in the highest-risk patients. This was quantified by calcu-
lating the number needed to treat to avoid 1 bleeding event,
which was only 42 in patients at high bleeding risk, 97 in
intermediate-risk patients, and 227 in low-risk patients
(16). Furthermore, the cost effectiveness of bivalirudin
through bleeding reduction is directly related to patients’
underlying bleeding risk. In a prior study at our institution,
hospital costs were reduced by $1,574/patient when bivali-
rudin was used in high-risk patients and $461/patient when
bivalirudin was used in intermediate-risk patients. However,
hospital costs increased by $705/patient when bivalirudin
was used in patients at low risk for bleeding (22).
There was a significant decrease in post-PCI bleeding
complications at our institution between 2007 and 2011,
driven by an approximately 40% reduction in bleeding in
patients at intermediate or high risk for bleeding. Impor-
tantly, there was no observed increase in bleeding in
low-risk patients, despite a decrease in bivalirudin use.
These findings provide evidence to support the increased
use of bivalirudin in higher-risk patients and suggest that
there is minimal risk associated with decreasing its use in
low-risk patients. This is important, because a more rational
use of bleeding avoidance strategies, such as bivalirudin use,
provides a practical strategy for achieving the aim of
improving patient outcomes while lowering costs.
The trends in bivalirudin use at our institution between
2007 and 2011 were not reflective of national PCI trends.
We have previously described a risk–treatment paradox,
namely that bivalirudin is used most commonly in low-risk
and least commonly in higher-risk patients, a pattern that
was also present at our institution before the implementa-
tion of prospective risk stratification. The changes observed
at our institution, without similar changes observed in the
rest of the country, suggest that bleeding risk is not intuitive
and that prospective risk stratification can support the more
rational application of bleeding avoidance strategies in
routine clinical practice. Nevertheless, the wide variability inbivalirudin use across operators at our institution suggests
that there is further room for improvement in creating a
more consistent healthcare environment that delivers care
tailored to patient risks. Supplementing our approach with
more standardized protocols based on bleeding risk, feed-
back reports, and financial incentives might further improve
the consistency of care. Ideally, a formal, site-level random-
ized clinical trial that incorporates prospective risk stratifi-
cation with additional interventions to improve care consis-
tency and better establish a more systematic approach to
bleeding risk management should be considered.
Study limitations. Our findings should be interpreted in
the context of the following potential limitations. First, this
was a retrospective, single-center study with a pre-/post-
implementation study design. However, the changes in
practice patterns were abrupt and differed substantially from
the rest of the NCDR, which served as a contemporary
control to support that the changes in practice at our
institution were not attributable to secular trends in care.
Second, although the observed reduction in bleeding was
temporally associated with the implementation of prospec-
tive bleeding risk assessment, causality cannot be concluded.
Other changes in care, such as re-education of support staff
on best practices for post-PCI sheath care, and the use of
smaller sheaths, radial artery access, and vascular closure
devices, may have influenced our findings. However, the
observed bleeding reductions were greatest in the subgroups
of patients at higher bleeding risk in which bivalirudin use
increased. This finding supports the notion that prospective
risk stratification may have contributed to bleeding reduc-
tion in these subgroups. Finally, routine bleeding risk
estimates were not estimated for STEMI patients and other
patients undergoing emergent PCI procedures. Because
patients undergoing emergent procedures are typically at
higher risk for bleeding complications, the ability to quickly
perform prospective risk stratification in such patients might
further increase the rational use of bivalirudin use in this
setting, beyond what was observed in this study.
Conclusions
In a single health system, the incorporation of individual-
ized bleeding risk estimates at the point of care led to
increased bivalirudin use in patients at intermediate and
high bleeding risk, lower use in patients with the least
potential to benefit, and reversal of the risk-treatment
paradox. During the same time period, a significant decrease
in post-PCI bleeding complications was observed in pa-
tients at intermediate and high risk for bleeding.
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